MSME (Udyam registered) Ministry of MSME
- Category
- Small (2023-24)
- Udyam number
- UDYAM-PY-03-0001532
Bymaa Laboratories Private Limited - pharma in Puducherry, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹15.25 Cr
▲ 8% YoY
Net profit · FY 2025
₹31.09 Lakh
Net margin 2%
EBITDA · FY 2025
₹1.31 Cr
EBITDA margin 8.6%
Authorised capital
₹9.25 Cr
Registered with MCA
Paid-up capital
₹9.23 Cr
Issued & subscribed
Open charges
₹7.02 Cr
Satisfied ₹9.07 Cr
Company age
20 yrs
Est. 2006
Employees · EPFO
66
Provident fund records
About Bymaa Laboratories Private Limited
Data last updated:
Bymaa Laboratories Private Limited is a private limited company based in Puducherry, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 November 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Pondicherry, under CIN U24231PY2006PTC002010. Its GSTIN is 34AABCL4500C1ZA (Puducherry).
The company has an authorised share capital of ₹9.25 Cr and a paid-up capital of ₹9.23 Cr. It was formerly known as Lexand Research Laboratories Private Limited and Lexend Research Laboratories Private Limited. It is led by directors including Chinnaiyan Raja (Whole-Time Director) and Mohammed Zubair.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A.19 20 21&22 Thirubuvanai Electronic Park Pipdic Industrial Estate Thirubuvanai., Puducherry, India – 605107.
As per the financials filed for FY 2025, the company reported a revenue of ₹15.25 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹31.09 Lakh (net margin 2%) and EBITDA of ₹1.31 Cr (EBITDA margin 8.6%). Revenue has grown at a compounded annual rate (CAGR) of 20% over three years and 25% over five years.
The company has about 66 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Bymaa Laboratories. As per MCA filings, the company has open charges of ₹7.02 Cr and satisfied charges of ₹9.07 Cr on record. Court records list 3 cases involving the company, including 3 filed against it; 3 cases are pending. The company has 9 deals on record (5 secondary share transfers, 4 funding rounds), with disclosed funding of ₹7.21 Cr; the latest was in June 2016. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 3 smaller; the largest is Ishita Drugs and Industries Limited with revenue of ₹15.33 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 4 overdue payments to 3 micro and small suppliers.
Bymaa Laboratories Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-PY-03-0001532). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bymaa.com.
Company details
CIN U24231PY2006PTC002010
Registration Number 002010
Incorporation Date 23 November 2006
ROC Pondicherry
Listing Status Unlisted
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-PY-03-0001532
Name history
Bymaa Laboratories has undergone 2 name changes throughout its history. The company was previously known as Lexand Research Laboratories Private Limited, and Lexend Research Laboratories Private Limited. The current legal name is Bymaa Laboratories Private Limited.
| Company Name | Status |
|---|---|
| Bymaa Laboratories Private Limited | Current |
| Lexand Research Laboratories Private Limited | Previous |
| Lexend Research Laboratories Private Limited | Previous |
Key People
Chinnaiyan Raja Whole-Time Director Mohammed Zubair Director Veera Raghavan Dharshini Director Recognitions & Rankings of Bymaa Laboratories
Contact details
Bymaa Laboratories Private Limited's registered office is in Puducherry, Puducherry. Its website is bymaa.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA.19 20 21&22 Thirubuvanai Electronic Park Pipdic Industrial Estate Thirubuvanai., Puducherry, India – 605107
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Bymaa Laboratories Private Limited, buy the company report.
Comprehensive company report
Bymaa Laboratories Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Bymaa Laboratories operates one associated brand: Bymaa Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturing and quality management services are offered by Bymaa Laboratories in Puducherry. | bymaa.com |
Business activity
The main business activity of Bymaa Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Bymaa Laboratories Private Limited, buy the company report.
Financials of Bymaa Laboratories Private Limited
FY 2025 filings availableBymaa Laboratories Private Limited reported revenue of ₹15.25 Cr (up 8% YoY) for FY 2025.
Revenue · FY 2025
₹15.25 Cr ▲ 8%
Net profit · FY 2025
₹31.09 Lakh margin 2%
EBITDA · FY 2025
₹1.31 Cr margin 8.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 8%
3 years · compounded
▲ 20%
5 years · compounded
▲ 25%
EBITDA CAGR growth
1 year
▲ 40%
3 years · compounded
▲ 411%
5 years · compounded
▲ 32%
Revenue has grown at a compounded annual rate (CAGR) of 25% over five years, including 8% growth in the latest year. EBITDA rose 40% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.31 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹31.09 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.6% | ||||
| Net Profit Margin | 2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Bymaa Laboratories Private Limited, buy the company report.
Board of directors of Bymaa Laboratories Private Limited
Bymaa Laboratories has 4 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mohammed Zubair | Director | 14 May 2015 | 11 Years 5 Months | Current |
| Veera Raghavan Dharshini | Director | 18 Aug 2021 | 5 Years 2 Months | Current |
| Chinnaiyan Raja | Whole-Time Director | 27 Apr 2017 | 9 Years 5 Months | Current |
| Abdul Hameed Jameel Moin | Director | 23 Feb 2015 | 11 Years 8 Months | Current |
Peer comparison
Bymaa Laboratories Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ishita Drugs and Industries Limited | ₹15.33 Cr (FY 2025) | -1.0% | Ahmedabad, Gujarat, India | |||
| Nuclotec Remedies Private Limited | ₹15.32 Cr (FY 2025) | -7.0% | New Delhi, Delhi, India | |||
| Vilin Bio Med Limited | ₹15.28 Cr (FY 2025) | -5.0% | Hyderabad, Telangana, India | |||
| Bymaa Laboratories Private Limitedthis company | ₹15.25 Cr (FY 2025) | ₹31.09 Lakh | 2% | 8.0% | 66 | Puducherry, India |
| Saviour Caps Private Limited | ₹15.24 Cr (FY 2025) | -1.0% | Bhopal, Madhya Pradesh, India | |||
| National Capsules Private Limited | ₹15.19 Cr (FY 2024) | -39.0% | Vidisha, Madhya Pradesh, India | |||
| Shiv Shakti Pharma Care Private Limited | ₹15.19 Cr (FY 2025) | -49.0% | Vapi, Gujarat, India |
To see the full peer comparison of Bymaa Laboratories Private Limited, buy the company report.
Shareholding
The shareholding of Bymaa Laboratories Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Bymaa Laboratories Private Limited, buy the company report.
Charges & borrowings
Open charges
₹7.02 Cr
Satisfied charges
₹9.07 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Sep 2024 | 101005028 | Indian Overseas Bank | ₹42 Lakh | Open | |
| 20 Jul 2024 | 100963521 | Indian Overseas Bank | ₹2.3 Cr | Open | |
| 15 Dec 2022 | 100681843 | Indian Overseas Bank | ₹4.3 Cr | Open | |
| 29 Oct 2007 | 10075398 | Indian Oversas Bank | ₹9.07 Cr | Satisfied |
To see the full charge records of Bymaa Laboratories Private Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Bymaa Laboratories Private Limited has 9 deals on record (5 secondary share transfers, 4 funding rounds), with disclosed funding of ₹7.21 Cr; the latest was in June 2016.
Total deals
9
Secondary share transfers
5
Funding rounds
4
Disclosed funding
₹7.21 Cr
Deals on record (5 of 9)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2016 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Feb 2015 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Dec 2013 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Dec 2013 | Funding round | ₹4.23 Cr | Investors: 4 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Bymaa Laboratories Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Bymaa Laboratories Private Limited has 3 court cases on record: 3 filed against it. All cases are pending.
Total cases
3
Filed against the company
3
Pending
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 2 | 2 |
| District courts | 1 | 1 | 1 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Interim or miscellaneous application | Filed against the company by Sun Pharma Laboratories Limited | Pending |
| High Court | Court case (COMIP) | Filed against the company by Sun Pharma Laboratories Limited | Pending |
| District court, Dholpur, Rajasthan | Criminal case | Filed against the company by State Government App | Pending |
To see the full case history of Bymaa Laboratories Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Bymaa Laboratories Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 4 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (3 of 3)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Shubham Pharmachem Pvt Ltd | |||
| Pharma Rule | |||
| Dazzle Corporation |
To see the full MSME payment records of Bymaa Laboratories Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Bymaa Laboratories Private Limited has a workforce of 66 employees on its EPFO records as of Mar 31, 2025, across 1 active EPFO establishment.
Employee count
66
Active EPFO establishments
1
Employee growth
15.79%
GST
Bymaa Laboratories has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 34AABCL4500C1ZA | Puducherry | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Bymaa Laboratories Private Limited, buy the company report.
Recent activity
Bymaa Laboratories Private Limited has 11 board changes on record since 2015: 4 appointments and 7 cessations. The latest: Abdul Hameed ceased to be Director on 10 Jun 2022.
AGM
Bymaa Laboratories Private Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Filing
Bymaa Laboratories Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pondicherry.
Charges
A charge with Indian Overseas Bank of Rs. 4.30 Cr registered on 15 Dec 2022 with Charge ID 100681843 was modified on 21 Mar 2025.
Charges
A charge with Indian Overseas Bank amounted to Rs. 0.42 Cr with Charge ID 101005028 was registered on 30 Sep 2024.
Charges
A charge with Indian Overseas Bank amounted to Rs. 2.30 Cr with Charge ID 100963521 was registered on 20 Jul 2024.
Charges
A charge with Indian Overseas Bank amounted to Rs. 4.30 Cr with Charge ID 100681843 was registered on 15 Dec 2022.
Ceased
Abdul Hameed ceased to be Director.
Ceased
Veera Raghavan Dharshini ceased to be Additional Director.
Ceased
Jeyaraman Kaartic ceased to be Director.
Appointed
Veera Raghavan Dharshini was appointed as Director.
Charges
A charge registered on 29 Oct 2007 via Charge ID 10075398 with Indian Oversas Bank was fully satisfied on 25 Jan 2019.
Ceased
Mohamed Sameer ceased to be Director.
9 earlier events are in the company report.
Frequently asked questions
Bymaa Laboratories is an active private limited company based in Puducherry, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 November 2006 (20+ years old) and is registered under CIN U24231PY2006PTC002010.
Bymaa Laboratories has 4 current directors:
- Chinnaiyan Raja - Whole-Time Director
- Mohammed Zubair - Director
- Veera Raghavan Dharshini - Director
- Abdul Hameed Jameel Moin - Director
The latest financial statements of Bymaa Laboratories on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Bymaa Laboratories is 34AABCL4500C1ZA, registered in Puducherry.
The CIN (Corporate Identification Number) of Bymaa Laboratories is U24231PY2006PTC002010. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Bymaa Laboratories has 3 court cases on record: 3 filed against it. 3 are pending. Most are in the high courts.
Bymaa Laboratories was incorporated on 23 November 2006, making it 20+ years old. It is registered with the Registrar of Companies, Pondicherry.
Bymaa Laboratories has 9 deals on record (5 secondary share transfers, 4 funding rounds), with disclosed funding of ₹7.21 Cr; the latest was in June 2016.
The peers of Bymaa Laboratories by revenue are Ishita Drugs and Industries Limited, Nuclotec Remedies Private Limited, Vilin Bio Med Limited, Saviour Caps Private Limited, National Capsules Private Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Abdul Hameed ceased to be Director on 10 Jun 2022. Veera Raghavan Dharshini ceased to be Additional Director on 29 Nov 2021. Jeyaraman Kaartic ceased to be Director on 20 Aug 2021. Bymaa Laboratories has 11 board changes on record in total.
Yes, Bymaa Laboratories is registered as a small enterprise under Udyam registration (number: UDYAM-PY-03-0001532).
Bymaa Laboratories has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 4 overdue payments to 3 micro and small suppliers. The latest return was filed on 29 May 2019.